Enrollment underway at Mackay Base Hospital in Queensland, Australia; additional sites in final activation stagesSARASOTA, Fla., April 20, ...
SARASOTA, Fla., March 06, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company advancing innovative treatments for concussion and brain-related health conditions, ...
Oragenics, Inc., a biotech company focused on intranasal therapeutics for brain-related conditions, announced that its Head of Business Development, Greg Gironda, will present at the 2025 BIO ...
On Thursday, Oragenics Inc. (NYSE:OGEN) announced that its lead candidate for treating concussion completed a study that indicates ONP-002 does not cause cardiotoxicity. ONP-002 is a new chemical ...
SARASOTA, Fla., July 16, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (OGEN), a biotechnology company developing intranasal therapeutics for brain-related conditions, today announced it has entered into a ...
HERMOSA BEACH, Calif.--(BUSINESS WIRE)--Ortega National Parks (ONP) announces that Nolan Capital, Inc., the family office of Peter Nolan, has become the company’s majority owner. This sale will enable ...
14d
Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury
Mackay Base Hospital activated March 31, 2026 as first clinical trial site; first patient dosed within days of activation — a signal of strong ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results